Phibro Animal Health (NASDAQ:PAHC) Shares Gap Up – What’s Next?

Phibro Animal Health Corporation (NASDAQ:PAHC)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $28.52, but opened at $29.94. Phibro Animal Health shares last traded at $30.00, with a volume of 41,780 shares.

Wall Street Analysts Forecast Growth

PAHC has been the topic of several analyst reports. Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a research report on Friday, February 6th. Citigroup cut their price target on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Zacks Research cut shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 21st. Wall Street Zen cut shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings cut shares of Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $38.80.

Phibro Animal Health Stock Up 3.9%

The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of 14.18, a price-to-earnings-growth ratio of 0.48 and a beta of 0.46. The firm’s 50 day moving average price is $46.67 and its two-hundred day moving average price is $45.23. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.04. The company had revenue of $383.54 million for the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Sell-side analysts anticipate that Phibro Animal Health Corporation will post 3.07 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 24th. Stockholders of record on Wednesday, June 3rd will be paid a dividend of $0.12 per share. The ex-dividend date is Wednesday, June 3rd. This represents a $0.48 annualized dividend and a dividend yield of 1.5%. Phibro Animal Health’s payout ratio is currently 20.60%.

Insider Buying and Selling at Phibro Animal Health

In other news, CEO Jack Bendheim sold 10,560 shares of the business’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $52.68, for a total transaction of $556,300.80. Following the transaction, the chief executive officer directly owned 80,360 shares in the company, valued at $4,233,364.80. The trade was a 11.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders have sold 74,928 shares of company stock worth $4,017,273. 50.13% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Cetera Investment Advisers grew its position in shares of Phibro Animal Health by 2.7% during the 1st quarter. Cetera Investment Advisers now owns 10,997 shares of the company’s stock worth $608,000 after purchasing an additional 293 shares in the last quarter. 1620 Investment Advisors Inc. lifted its holdings in shares of Phibro Animal Health by 77.4% during the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock worth $25,000 after acquiring an additional 295 shares during the period. Tudor Investment Corp ET AL lifted its holdings in shares of Phibro Animal Health by 3.4% during the 3rd quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock worth $412,000 after acquiring an additional 338 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Phibro Animal Health by 2.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock worth $332,000 after acquiring an additional 363 shares during the period. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after acquiring an additional 386 shares during the period. Institutional investors and hedge funds own 99.34% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.